66 Billion? That’s a lot of Botox.<\/h3>\n
According to the sources, this take-over by Actavis, is worth $66 billion.<\/p>\n In the past two years, Actavis has purchased Forest Laboratories and Warner Chilcott. \u00a0 Actavis’ CEO is Brent Saunders. \u00a0He used to run Forest Laboratories. \u00a0Actavis is headquartered in Dublin, Ireland and has administrative offices in New Jersey.<\/p>\n Pershing Square Capital Management owns 9.7% of Allergan shares. \u00a0Valeant indicated that it may not try to beat Actavis’s offer. \u00a0Bill Ackerman and Valeant stand to benefit from the increased share price for Allergan; thus they wouldn’t lose either way.<\/p>\n This is a win-win-win for the three A’s: \u00a0Actavis, Allergan, Ackerman. \u00a0And it also seems to be a win for Valeant who will get 15% of Ackerman’s profits from the price increase in Allergan’s stock (which he owns nearly 10% of Allergan stock). \u00a0I also think it will be a win for Botox injectors and consumers. \u00a0Actavis will try to be more efficient with it’s administration of Allergan – with further cost cutting and unification of efforts. \u00a0And they have pledged to continue to have research and development within the Allergan family of products. \u00a0And most importantly in the end, I think the consumers (and doctors) will benefit. \u00a0I feel that the Valeant\/Allergan merger (Vallergant – I’ve called it), might have cut too many costs and we’d lose on research\/development. \u00a0Thus the new merger of Allergan and Actvis – there would be a better balance with continued research and developement. \u00a0So it will be a 6 way win-win-win-win-win-win: \u00a0Actavis, Allergan, Ackerman, Valeant, doctors\/Botox-injectors, and patients. \u00a0That’s how you do mergers! \u00a0 I certainly hope so. \u00a0Time will tell, and I hope to be here to talk about it.<\/p>\n <\/p>\n Sources:<\/p>\n Link to Allergan goes with Actavis instead of Valeant \/ Ackerman<\/a><\/p>\n Ackerman\/Valeant walks<\/a>\u00a0away from Allergan<\/p>\n Wikipedia article on Actavis<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" BOTOX wars The Botox company, Allergan, has consented to be bought by generic pharmaceutical maker, Actavis for $219 a share. \u00a0This gets in the way of\u00a0the hostile takeover attempts led by Valeant Pharmaceuticals and hedge fund man, Bill Ackerman of Pershing Square Capital Management. \u00a0 But it might be possible for Valeant to out-bid Actavis? … Continue reading Allergan Merger \/ Actavis Takeover<\/span> ![\"botox-bottles-botox-blog-2.jpg\"](\"https:\/\/www.injectionartistry.com\/botoxblog\/wp-content\/uploads\/2013\/07\/botox-bottles-botox-blog-2-300x78.jpg\")
<\/a>Who is Actavis?<\/h3>\n
Who are the losers? Nobody?<\/h3>\n
My thoughts<\/h3>\n